|
|||||
|
|
Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide |
|
| Authors: | Yehuda Zadik Sharon Elad Anat Shapira |
| Affiliation: | 1. Department of Oral Medicine, Sedation and Maxillofacial Imaging, Hadassah-Hebrew University School of Dental Medicine, Jerusalem, Israel;2. Department of Oral Medicine, The Oral and Maxillofacial Center, Medical Corps, Israel Defense Forces, Tel Hashomer, Israel;3. Division of Oral Medicine, Hospital General Dentistry, Eastman Institute for Oral Health, University of Rochester Medical Center, Rochester, NY, USA;4. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA;5. Pharmacy Division, Hadassah-Hebrew University Medical Center, Jerusalem, Israel |
| Abstract: | Introduction: The oral mucosa is commonly involved in chronic graft-versus-host disease (cGVHD). Oral mucosal cGVHD markedly affect individual’s daily function and wellbeing. In some cases, it might become a life threating complication. Areas covered: This article describes the rationale for treatment, method of topical application in the oral cavity, evidence supporting the topical administration of dexamethasone and budesonide for oral cGVHD, and their adverse effects. Expert opinion: Evidence supports the use of topical dexamethasone and budesonide for treatment of oral cGVHD. Topical corticosteroid choice for oral cGVHD, takes into consideration the potency, bioavailability, preferred concentration, and possible adverse effects. Budesonide’s pharmacological characteristics mark it as a preferable topical agent for oral cGVHD. |
| Keywords: | Budesonide chronic graft-versus-host disease dexamethasone hematopoietic stem cell transplantation oral medicine oral mucosa pain |